12/18
04:36 pm
incr
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/12
04:16 pm
incr
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/3
08:30 am
incr
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
Low
Report
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
10/8
09:40 am
incr
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow [Yahoo! Finance]
Low
Report
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow [Yahoo! Finance]
10/8
09:40 am
incr
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Low
Report
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
10/8
09:02 am
incr
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Medium
Report
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow